Global pharmaceutical major Lupin Limited has announced the successful completion of its acquisition of VISUfarma B.V., a prominent European specialty pharmaceutical company. This strategic move significantly bolsters Lupin’s ophthalmology portfolio by adding over 60 branded products. The acquisition is set to strengthen the company’s commercial footprint across key European markets, including the UK, France, Spain, Germany, and Italy, while accelerating the growth of its specialized healthcare franchise.
Strategic Expansion into European Ophthalmology
Lupin has finalized the acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a significant milestone in its global expansion strategy. By integrating VISUfarma’s operations, Lupin adds a diverse range of 60+ innovative eye health products, addressing conditions such as dry eye, glaucoma, blepharitis, and retinal health. This portfolio is supported by a robust commercial infrastructure and a highly experienced team with deep regional market expertise.
Driving Future Growth
The deal aligns with Lupin’s commitment to addressing the rising global demand for eye care, a need fueled by an aging population and an increase in diabetes-related eye complications. According to the company, the acquisition is expected to be immediately accretive, providing a solid foundation for further growth in Europe. Vinita Gupta, CEO of Lupin, noted that this move is a key step in accelerating the build-out of the company’s specialty franchise.
About the Acquired Business
VISUfarma was founded in 2016 through the merger of the Italian company Visufarma SpA and the European commercial division of Nicox SA. Focused exclusively on ophthalmology, the company demonstrated strong financial performance with €53 million in revenue recorded during the 2025 calendar year. The integration of this established business is expected to leverage Lupin’s global vision and commitment to improving patient health outcomes across international markets.
Source: BSE
